Company Website:
http://www.foundationmedicine.com
CAMBRIDGE, Mass. -- (Business Wire)
Foundation
Medicine, Inc. (NASDAQ:FMI) today announced that financial results
for the company’s first quarter ended March 31, 2014 will be released on
Wednesday, May 7, 2014. The management team will host a conference call
discussing the company’s financial results and recent developments on
Wednesday, May 7, 2014 at 4:30 p.m. ET. The call can be accessed by
dialing 1-855-420-0652 (domestic) or 1-484-365-2939 (international) five
minutes prior to the start of the call and providing the passcode
29386961.
The live, listen-only webcast of the conference call can be accessed by
visiting the investors section of the Foundation Medicine website at
investors.foundationmedicine.com. A replay of the webcast will be
available shortly after the conclusion of the call and archived on the
company’s website for two weeks following the call.
About Foundation Medicine
Foundation
Medicine® (NASDAQ: FMI) is a molecular information
company dedicated to a transformation in cancer care in which treatment
is informed by a deep understanding of the genomic changes that
contribute to each patient’s unique cancer. The company’s clinical
assays, FoundationOneTM
for solid tumors and FoundationOneTM
Heme for hematologic malignancies, sarcomas and pediatric cancers, each
provide a fully informative genomic profile to identify the molecular
alterations in a patient’s tumor and match them with relevant targeted
therapies and clinical trials. Foundation Medicine’s molecular
information platform aims to improve day-to-day care for patients by
serving the needs of clinicians, academic researchers and drug
developers to help advance the science of molecular medicine in cancer.
For more information, please visit www.FoundationMedicine.com
or follow Foundation Medicine on Twitter
(@FoundationATCG).
Foundation Medicine® is a registered trademark, and FoundationOneTM
is a trademark, of Foundation Medicine, Inc.
Contacts:
Media Contact:
Pure Communications, Inc.
Dan Budwick,
973-271-6085
dan@purecommunicationsinc.com
or
Investor
Contact:
Khaled Habayeb, 617-418-2283
ir@foundationmedicine.com
Source: Foundation Medicine, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.